<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01749163</url>
  </required_header>
  <id_info>
    <org_study_id>PancClamp</org_study_id>
    <nct_id>NCT01749163</nct_id>
  </id_info>
  <brief_title>Hyperglycemia and the Extra-pancreatic Effect of Incretins</brief_title>
  <official_title>Determining the Extra-pancreatic Effects of Incretin Hormones During Euglycemic and Hyperglycemic Pancreatic Clamps</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rigshospitalet, Denmark</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rigshospitalet, Denmark</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Incretin hormones (GLP-1 and GIP) released from the intestine in response to meal ingestion
      augment insulin secretion from the pancreas to help maintain glycemic control. Studies in
      vitro and in vivo have shown that these incretin hormones also have functional effects in
      other tissues independent of the insulin secretory response. Both GLP-1 and GIP stimulate
      insulin secretion in a glucose-dependent manner, however the glucose-dependency of their
      extra-pancreatic effects has not been examined in vivo. By using pancreatic clamp methodology
      during euglycemic and hyperglycemic conditions we will test the hypothesis that
      extra-pancreatic effects of GLP-1 and GIP are glucose-dependent.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2012</start_date>
  <completion_date type="Actual">March 2014</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Glucose metabolism</measure>
    <time_frame>up to 4 hours</time_frame>
    <description>Pancreatic clamp will be performed including infusion of somatostatin and replacement of basal insulin, glucagon, and growth hormone. During pancreatic clamps, euglycemia (5 mM) will be maintained via exogenous glucose infusion for the first 2-hours, followed by hyperglycemia (+5 mM) for the final 2-hours. An infusion of the stable isotope [U13C]glucose will be performed to assess glucose kinetics. Expired air will be collected for the analysis of [U13C]glucose into 13CO2.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Lipid metabolism</measure>
    <time_frame>up to 4 hours</time_frame>
    <description>An infusion of the stable isotope [D5]glycerol will be performed to assess glycerol kinetics.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Endothelial function</measure>
    <time_frame>Baseline, 2 hours, and 4 hours</time_frame>
    <description>Ultrasound Doppler will be used to examine lower and upper limb blood flow and flow-mediated dilation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Signaling</measure>
    <time_frame>Baseline, 2 hours, and 4 hours</time_frame>
    <description>Skeletal muscle (vastus lateralis) and subcutaneous abdominal adipose biopsies will be obtained under local anaesthetic by the Bergstrom needle technique. Intracellular signalling related to glucose and lipid metabolism will be measured.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Extra-pancreatic Incretin Effect</condition>
  <condition>Glucose Effectiveness</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Saline will be coninfused during the pancreatic clamp</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GIP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GIP will be infused intravenously during the pancreatic clamp at 1.5 pmol/kg/min</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GLP-1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GLP-1 will be infused intravenously during the pancreatic clamp at 0.5 pmol/kg/min</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Saline</intervention_name>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GIP</intervention_name>
    <arm_group_label>GIP</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GLP-1</intervention_name>
    <arm_group_label>GLP-1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age 18-60 years

          -  BMI 18-30 kg/m2

          -  Male

          -  Normal glycemic control (fasting glucose &lt;5.6 mM)

        Exclusion Criteria:

          -  Evidence of chronic disease

          -  Smoking

          -  Active weight loss (&gt;2 kg in previous 6 months)

          -  Treatment with drugs known to affect our outcome varaibles
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas PJ Solomon, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rigshospitalet, Denmark</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <state>Capital Region</state>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>December 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 11, 2012</study_first_submitted>
  <study_first_submitted_qc>December 12, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 13, 2012</study_first_posted>
  <last_update_submitted>December 2, 2014</last_update_submitted>
  <last_update_submitted_qc>December 2, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 3, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Rigshospitalet, Denmark</investigator_affiliation>
    <investigator_full_name>Thomas Solomon</investigator_full_name>
    <investigator_title>Senior Researcher</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Incretins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

